An observational study of once-daily modified-release methylphenidate in ADHD: Effectiveness on symptoms and impairment, and safety

European Child and Adolescent Psychiatry

Volumn 20, Issue SUPPL. 2, 2011, Pages

  Döpfner, Manfred ^a   Görtz Dorten, Anja ^a   Breuer, Dieter ^a   Rothenberger, Aribert ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

ADHD; Methylphenidate; Modified release; Observational study; Post marketing surveillance study

Indexed keywords

METHYLPHENIDATE;

ADOLESCENT; AGGRESSION; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMPULSION; DECREASED APPETITE; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL PAIN; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; ONYCHOPHAGIA; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD; SIDE EFFECT; SLEEP DISORDER; TIC; TREATMENT OUTCOME; TREMOR;

ADMINISTRATION, ORAL; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GERMANY; HUMANS; MEDICATION ADHERENCE; METHYLPHENIDATE; PSYCHOMOTOR PERFORMANCE; SAFETY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84855215716     PISSN: 10188827     EISSN: 1435165X     Source Type: Journal    
DOI: 10.1007/s00787-011-0202-4     Document Type: Article

References (46)

1. Adler LA, Chua HC (2002) Management of ADHD in adults. J Clin Psychiatry 63(Suppl 12):29-35 (Pubitemid 36025585)
2. American Psychiatric Association (2000) Attention-deficit and disruptive behavior disorders. Attention-deficit/hyperactivity disorder. Diagnostic and statistical manual of mental disorders. 4th edn. American Psychiatric Association, Arlington, pp 85-103
3. Anderson VR, Keating GM (2006) Methylphenidate controlleddelivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attentiondeficit hyperactivity disorder. Paediatr Drugs 8:319-333 (Pubitemid 44607537)
4. Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E (2006) Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15:476-495 (Pubitemid 46020533)
5. Barkley RA, Fischer M, Smallish L, Fletcher K (2003) Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 111:97-109 (Pubitemid 36071038)
6. Biederman J, Faraone SV (2005) Attention-deficit hyperactivity disorder. Lancet 366:237-248 (Pubitemid 40981053)
7. Breuer D, Görtz-Dorten A, Rothenberger A, Döpfner M (2011) Assessment of daily profiles of ADHD and ODD symptoms, and symptomatology related to ADHD medication, by parent and teacher ratings. Eur Child Adolesc Psychiatry. doi:10.1007/s00787-011-0206-0
8. Breuer D, Wolff MT, Dopfner M (2009) The assessment of Attention Deficit Hyperactivity Disorder (ADHD) by teacher ratings - validity and reliability of the FBB-HKS. Z Kinder Jugendpsychiatr Psychother 37:431-440
9. Bruhl B, Dopfner M, Lehmkuhl G (2000) Der Fremdbeurteilungsbogen für hyperkinetische Störungen (FBB-HKS)- Prävalenz hyperkinetischer Störrungen im Elternurteil und psychometrische Kriterien. Kindheit und Entwicklung 9. S.:116-126
10. Cohen J (1988) Statistical power analysis for the behavioural sciences. Lawrence Erlbaum Associates, Hillsdale
11. Cutting LE, Koth CW, Mahone EM, Denckla MB (2003) Evidence for unexpected weaknesses in learning in children with attention-deficit/hyperactivity disorder without reading disabilities. J Learn Disabil 36:259-269 (Pubitemid 36650028)
12. Dirksen SJ, D'Imperio JM, Birdsall D, Hatch SJ (2002) A postmarketing clinical experience study of Metadate CD. Curr Med Res Opin 18:371-380 (Pubitemid 35448533)
13. Döpfner M, Görtz-Dorten A, Lehmkuhl G (2008) Diagnostik- System für psychische Störungen nach ICD-10 und DSM-IV für Kinder- und Jugendliche (DISYPS-II). Huber, Bern
14. Döpfner M, Lehmkuhl G (1998) Diagnostik-System für Psychische Störungen im Kindes- und Jugendalter nach ICD-10 und DSM-IV (DISYPS-KJ). Huber, Bern
15. DuPaul GJ, McGoey KE, Eckert TL, VanBrakle J (2001) Preschool children with attention-deficit/hyperactivity disorder: impairments in behavioral, social, and school functioning. J Am Acad Child Adolesc Psychiatry 40:508-515 (Pubitemid 32374267)
16. Erhart M, Döpfner M, Ravens-Sieberer U (2008) Psychometric properties of two ADHD questionnaires: comparing the Conners' scale and the FBB-HKS in the general population of German children and adolescents-results of the BELLA study. Eur Child Adolesc Psychiatry 17(Suppl 1):106-115
17. Faraone SV, Biederman J, Mick E (2006) The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 36:159-165 (Pubitemid 43126140)
18. Findling RL, Katic A, Rubin R, Moon E, Civil R, Li Y (2010) A 6-month, open-label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 20:365-375
19. Findling RL, Quinn D, Hatch SJ, Cameron SJ, DeCory HH, McDowell M (2006) Comparison of the clinical efficacy of twicedaily Ritalin and once-daily Equasym XL with placebo in children with Attention Deficit/Hyperactivity Disorder. Eur Child Adolesc Psychiatry 15:450-459 (Pubitemid 46020530)
20. Gonzalez MA, Pentikis HS, Anderl N, Benedict MF, DeCory HH, Dirksen SJ, Hatch SJ (2002) Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 40:175-184 (Pubitemid 34296385)
21. Goodman R (1997) The Strengths and Difficulties Questionnaire: a research note. J Child Psychol Psychiatry 38:581-586 (Pubitemid 27341892)
22. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Dopfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E (2010) European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 20:17-37
23. Greenhill LL, Findling RL, Swanson JM (2002) A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 109:E39
24. Heger S, Trott GE, Meusers M, Schulz E, Rothenberger A, Rettig K, Medori R, Schreiner A, Remschmidt H (2006) Switching from a short-acting to a long-acting methylphenidate preparation: a multicentre, open study in children with ADHD. Z Kinder Jugendpsychiatr Psychother 34:257-265 (Pubitemid 44204675)
25. Horrigan JP, Kohli RR (2002) The impact of dosing frequency on psychostimulant compliance in ADHD. NIMH-42nd Annual NCDEU Meeting Poster 56
26. Lee SI, Hong SD, Kim SY, Kim EJ, Kim JH, Kim JH, Park MK, Park S, Park JH, Oh EY, Lim TS, Cheong S, Cho IH, Choi JW (2007) Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 31:210-216 (Pubitemid 44959275)
27. Lowe TL, Cohen DJ, Detlor J, Kremenitzer MW, Shaywitz BA (1982) Stimulant medications precipitate Tourette's syndrome. JAMA 247:1729-1731 (Pubitemid 12192968)
28. Morris SB (2008) Estimating effect sizes from pretest-posttestcontrol group designs. Organ Res Methods 11:364-386
29. NIH (2000) National Institutes of Health consensus development conference statement: diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry 39:182-193
30. Palumbo D, Spencer T, Lynch J, Co-Chien H, Faraone SV (2004) Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. J Child Adolesc Psychopharmacol 14:185-194 (Pubitemid 38988785)
31. Patrick KM (1987) Pharmacokinetics and actions of methylphenidate. In: Meltzer H (ed) Psychopharmacology, the third generation of progress. Raven Press, New York, pp 1387-1395
32. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD (2001) Once-a-day Concerta methylphenidate versus three-timesdaily methylphenidate in laboratory and natural settings. Pediatrics 107:E105
33. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164:942-948 (Pubitemid 46972911)
34. Poncin Y, Sukhodolsky DG, McGuire J, Scahill L (2007) Drug and non-drug treatments of children with ADHD and tic disorders. Eur Child Adolesc Psychiatry 16(Suppl 1):78-88
35. Remschmidt H, Hoare P, Ettrich C, Rothenberger A, Santosh P, Schmidt M, Spender Q, Tamhne R, Thompson M, Tinline C, Trott GE, Medori R (2005) Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study. Eur Child Adolesc Psychiatry 14:297-304
36. Roessner V, Robatzek M, Knapp G, Banaschewski T, Rothenberger A (2006) First-onset tics in patients with attention-deficithyperactivity disorder: impact of stimulants. Dev Med Child Neurol 48:616-621
37. Rosnow RL, Rosenthal R (2009) Effect sizes: why, when and how to use them. J Psychol 217:6-14
38. Rothenberger A, Becker A, Erhart M, Wille N, Ravens-Sieberer U (2008) Psychometric properties of the parent strengths and difficulties questionnaire in the general population of German children and adolescents: results of the BELLA study. Eur Child Adolesc Psychiatry 17(Suppl 1):99-105
39. Rothenberger A, Becker A, Breuer D, Döpfner M (2011) An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence. Eur Child Adolesc Psychiatry. doi:10.1007/s00787-011-0203-3
40. Shire Pharmaceuticals. Equasym XL SPC. 2011
41. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Owens EB, Pelham WE, Schiller E, Severe JB, Simpson S, Vitiello B, Wells K, Wigal T, Wu M (2001) Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 40:168-179 (Pubitemid 32111020)
42. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ (2004) A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/ hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 113:e206-e216
43. Van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM (2008) Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis. Clin Psychol Rev 28:783-800
44. Wigal SB, Sanchez DY, DeCory HH, D'Imperio JM, Swanson JM (2003) Selection of the optimal dose ratio for a controlleddelivery formulation of methylphenidate. J Appl Res 3:46-63 (Pubitemid 37012428)
45. Woerner W, Becker A, Friedrich C, Klasen H, Goodman R, Rothenberger A (2002) Normal values and evaluation of the German parents' version of Strengths and DIfficulties Questionnaire (SDQ): results of a representative field study. Z Kinder Jugendpsychiatr Psychother 30:105-112 (Pubitemid 34477535)
46. World Health Organization. International Classification of Diseases (ICD-10) (1992) Geneva